Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ascorbic acid and quinone compounds for treating chagas disease

a technology of ascorbic acid and quinone, which is applied in the direction of antiparasitic agents, organic active ingredients, drug compositions, etc., can solve the problems of high toxicity, variable efficacy of benznidazole and nifurtimox,

Pending Publication Date: 2019-11-14
IC MEDTECH CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a new method of treating, preventing, or alleviating symptoms of Chagas disease, a chronic disease caused by a parasite. The method involves giving a subject either ascorbic acid (vitamin C) or a combination of ascorbic acid and a quinone compound. The patent also describes a method of inhibiting parasitic growth by contacting a parasite with ascorbic acid or a combination of ascorbic acid and a quinone compound. The technical effects of this patent are the development of a new treatment strategy for Chagas disease and the discovery of novel compounds that can inhibit parasite growth.

Problems solved by technology

Benznidazole and nifurtimox are also known to have variable efficacy and high toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ascorbic acid and quinone compounds for treating chagas disease
  • Ascorbic acid and quinone compounds for treating chagas disease
  • Ascorbic acid and quinone compounds for treating chagas disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Trypanocidal Effect of Vitamins C and K3

[0207]To evaluate the trypanocidal effect of the VC and VK3 combination on epimastigotes, trypomastigotes, and amastigotes, the combination Index method as described by Chou and Talalay was applied. Chou et al., Adv. Enzyme Regul. 1984, 22, 27-55.

[0208]Epimastigote forms (1×106 parasites / mL) in the exponential growth phase were resuspended in LIT medium supplemented with 10% FBS. The vitamins were added to the cell suspension, alone or in combination (0.35-2.84 mM VC and 1.0-9.0 μM VK3), in 24-well plates and incubated at 28° C. The number of epimastigote forms was determined by counting in a Neubauer hemocytometer after 96 hrs.

[0209]To evaluate activity against trypomastigote forms, parasites were obtained from the supernatant of infected LLCMK2 cells. Trypomastigote forms (1×107 parasites / mL) were resuspended in the presence of DMEM supplemented with 10% FBS and different concentrations of both vitamins, alone or in combination (0.09-1.42 m...

example 2

[0213]The morphological and ultrastructural effect of vitamins C and K3

[0214]For scanning electron microscopy (SEM), epimastigote forms (1×106 parasites / mL) were treated with 0.61 mM VC and 1.90 μM VK3, alone or in combination, for 72 hrs at 28° C. Trypomastigote forms (1×107 parasites / mL) were treated with 0.20 mM VC and 0.35 μM VK3, alone or in combination, for 24 hrs at 37° C. in a 5% CO2 atmosphere. Intracellular amastigotes were treated with 0.18 mM VC and 0.30 μM VK3, alone or in combination, for 24 hrs at 37° C. in a 5% CO2 atmosphere. After incubation, the parasites were harvested, washed twice in PBS, and fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at 4° C. The parasites were then placed on a glass support that was covered with poly-L-lysine, dehydrated in an ascending series of ethanol, critical-point dried with CO2, coated with gold, and observed in a Shimadzu SS-550 scanning electron microscope. For intracellular amastigotes, we used the fracture ta...

example 3

The Effect of Vitamins C and K3 on the Generation of Total ROS and NO

[0218]The production of total reactive oxygen species (total ROS) was evaluated in parasitic forms after exposure to VC and VK3 using the probe H2DCFDA. Epimastigote forms (1×106 parasites / mL) were evaluated after exposure to 0.61 mM VC and 1.90 μM VK3, alone and in combination, for 24 hrs at 28° C. Trypomastigote forms (1×107 parasites / mL) were evaluated after exposure to 0.20 mM VC and 0.35 μM VK3, alone and in combination, for 24 hrs at 37° C. in a 5% CO2 atmosphere. Amastigote forms (1×107 parasites / mL) were evaluated after exposure to 0.18 mM VC and 0.30 μM VK3, alone and in combination, for 24 hrs at 37° C. in a 5% CO2 atmosphere. Hydrogen peroxide (H2O2; 20.0 μM) was used as a positive control. Afterward, the parasites were centrifuged, washed, and resuspended in PBS. Parasites were loaded with 10.0 μM of the permeant probe H2DCFDA in the dark for 45 min. Total ROS were measured as an increase in fluorescenc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molar ratioaaaaaaaaaa
molar ratioaaaaaaaaaa
molar ratioaaaaaaaaaa
Login to View More

Abstract

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application claims priority to U.S. Provisional Patent Application No. 62 / 430,758, filed Dec. 6, 2016, the disclosure of which is incorporated herein by reference in its entirety.FIELD[0002]Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.BACKGROUND[0003]Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the protozoan Trypanosoma cruzi, affecting millions of people worldwide. World Health Organization. Chagas diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/375A61K9/00A61K31/122A61K31/4168A61K31/541A61P33/02
CPCA61P33/02A61K9/0053A61K31/4168A61K31/122A61K31/541A61K31/375A61K2300/00A61P33/14Y02A50/30
Inventor LAUTENSCHLAGER, SUELI DE OLIVEIRA SILVADESOTI, VÂNIA CRISTINANAKAMURA, CELSO VATARUXIMENES, VALDECIR FARIAS
Owner IC MEDTECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com